PubRank

A Colao

Author PubWeight™ 154.10‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 2009 2.96
2 Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2008 2.70
3 Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab 2010 2.16
4 Impairment of GH secretion in adults with primary empty sella. J Endocrinol Invest 2002 2.09
5 Treatment of skeletal impairment in patients with endogenous hypercortisolism: when and how? Osteoporos Int 2013 2.00
6 Predictive value of pentagastrin test for preoperative differential diagnosis between C-cell hyperplasia and medullary thyroid carcinoma in patients with moderately elevated basal calcitonin levels. Clin Endocrinol (Oxf) 2009 1.46
7 Spinal deformity index in patients with type 2 diabetes. Endocrine 2012 1.45
8 Growth hormone and heart performance. A novel mechanism of cardiac wall stress regulation in humans. Eur Heart J 1997 1.43
9 The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin Endocrinol (Oxf) 2000 1.40
10 CV 205-502 treatment in therapy-resistant acromegalic patients. Eur J Endocrinol 1995 1.40
11 [Effectiveness of and tolerability to oral desmopressin in the treatment of central diabetes insipidus]. Minerva Med 1992 1.39
12 ACROSTUDY: the Italian experience. Endocrine 2014 1.38
13 Endoscopic endonasal transsphenoidal approach: outcome analysis of 100 consecutive procedures. Minim Invasive Neurosurg 2002 1.35
14 Primary empty sella: Why and when to investigate hypothalamic-pituitary function. J Endocrinol Invest 2010 1.21
15 Clinical characterization of familial isolated pituitary adenomas. J Clin Endocrinol Metab 2006 1.17
16 Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. Eur J Endocrinol 2008 1.14
17 Diagnostic and prognostic implications of the World Health Organization classification of neuroendocrine tumors. J Endocrinol Invest 2008 1.14
18 Structured exercise training programme versus hypocaloric hyperproteic diet in obese polycystic ovary syndrome patients with anovulatory infertility: a 24-week pilot study. Hum Reprod 2007 1.10
19 Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. J Clin Endocrinol Metab 1993 1.07
20 Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 2001 1.01
21 Endothelial dysfunction in PCOS: role of obesity and adipose hormones. Am J Med 2006 1.01
22 Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg). J Clin Endocrinol Metab 2000 0.98
23 Recombinant growth hormone (GH) therapy in GH-deficient adults: a long-term controlled study on daily versus thrice weekly injections. J Clin Endocrinol Metab 2000 0.96
24 Longitudinal study of vasopressin-cell antibodies and of hypothalamic-pituitary region on magnetic resonance imaging in patients with autoimmune and idiopathic complete central diabetes insipidus. J Clin Endocrinol Metab 2002 0.96
25 Effects of various antireabsorptive treatments on bone mineral density in hypogonadal young women after allogeneic stem cell transplantation. Bone Marrow Transplant 2006 0.96
26 Predictors of morbidity and mortality in acromegaly: an Italian survey. Eur J Endocrinol 2012 0.96
27 Shortened interval of long-acting octreotide administration is effective in patients with well-differentiated neuroendocrine carcinomas in progression on standard doses. J Endocrinol Invest 2011 0.95
28 Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. J Endocrinol Invest 2009 0.95
29 The molecular causes of thyroid dysgenesis: a systematic review. J Endocrinol Invest 2013 0.95
30 Thyroid nodules treated with percutaneous radiofrequency thermal ablation: a comparative study. J Clin Endocrinol Metab 2012 0.95
31 Natural history of gastro-entero-pancreatic and thoracic neuroendocrine tumors. Data from a large prospective and retrospective Italian epidemiological study: the NET management study. J Endocrinol Invest 2011 0.94
32 Cardiovascular complications in acromegaly. Minerva Endocrinol 2004 0.94
33 [Usefulness of color echo Doppler with power Doppler in the diagnosis of hypoechoic thyroid nodules: work in progress]. Radiol Med 1996 0.92
34 Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study. J Cell Mol Med 2012 0.92
35 Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults. J Endocrinol Invest 2008 0.92
36 Circulating levels of cytochrome C, gamma-glutamyl transferase, triglycerides and unconjugated bilirubin in overweight/obese patients with non-alcoholic fatty liver disease. J Biol Regul Homeost Agents 2011 0.91
37 Successful treatment of a patient with a thymoma and pure red-cell aplasia with octreotide and prednisone. N Engl J Med 1997 0.91
38 The biological characterization of neuroendocrine tumors: the role of neuroendocrine markers. J Endocrinol Invest 2008 0.91
39 Complete remission of Nelson's syndrome after 1-year treatment with cabergoline. J Endocrinol Invest 1999 0.90
40 Endocrine dysfunction in patients with Fabry disease. J Clin Endocrinol Metab 2006 0.90
41 Involvement of hypothalamus autoimmunity in patients with autoimmune hypopituitarism: role of antibodies to hypothalamic cells. J Clin Endocrinol Metab 2012 0.90
42 Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur J Endocrinol 1998 0.90
43 Left ventricular function in young adults with childhood and adulthood onset growth hormone deficiency. Clin Endocrinol (Oxf) 1998 0.89
44 The growth hormone response to hexarelin in children: reproducibility and effect of sex steroids. J Clin Endocrinol Metab 1997 0.89
45 High variability in baseline urinary free cortisol values in patients with Cushing's disease. Clin Endocrinol (Oxf) 2013 0.89
46 The cardiovascular system in growth hormone excess and growth hormone deficiency. J Endocrinol Invest 2012 0.89
47 Glutathione peroxidase (GPX) activity in seminal plasma of healthy and infertile males. J Endocrinol Invest 2002 0.88
48 Lung volumes and respiratory muscle strength in adult patients with childhood- or adult-onset growth hormone deficiency: effect of 12 months' growth hormone replacement therapy. Eur J Endocrinol 1996 0.88
49 Is growth hormone bad for your heart? Cardiovascular impact of GH deficiency and of acromegaly. J Endocrinol 1997 0.87
50 Spine abnormalities and damage in patients cured from Cushing's disease. Pituitary 2001 0.87
51 Growth hormone status in morbidly obese subjects and correlation with body composition. J Endocrinol Invest 2006 0.87
52 Impaired cardiac performance in GH-deficient adults and its improvement after GH replacement. Am J Physiol 1994 0.87
53 Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab 1998 0.86
54 Power Doppler improves the diagnostic accuracy of color Doppler ultrasonography in cold thyroid nodules: follow-up results. Horm Res 1999 0.86
55 The GH-IGF system in amyotrophic lateral sclerosis: correlations between pituitary GH secretion capacity, insulin-like growth factors and clinical features. Eur J Neurol 2009 0.86
56 Analysis of color Doppler signal intensity variation after levovist injection: a new approach to the diagnosis of thyroid nodules. J Ultrasound Med 2001 0.86
57 Effects of physical exercise on the female reproductive system. Minerva Endocrinol 2013 0.85
58 Metabolic and cardiovascular consequences of polycystic ovary syndrome. Minerva Ginecol 2008 0.85
59 Thyroid function in Fabry disease before and after enzyme replacement therapy. Minerva Endocrinol 2011 0.85
60 Endoscopic endonasal transsphenoidal approach: an additional reason in support of surgery in the management of pituitary lesions. Skull Base Surg 1999 0.85
61 Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease. Clin Endocrinol (Oxf) 1998 0.85
62 Impairment of lung volumes and respiratory muscle strength in adult patients with growth hormone deficiency. Eur J Endocrinol 1995 0.84
63 Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients. Horm Metab Res 2011 0.84
64 Somatostatin receptor distribution and function in immune system. Dig Liver Dis 2004 0.84
65 Estrogens and health in males. Mol Cell Endocrinol 2001 0.84
66 Growth hormone, prolactin, and sexuality. J Endocrinol Invest 2012 0.84
67 Insulin-like growth factor-1 predicts cognitive functions at 2-year follow-up in early, drug-naïve Parkinson's disease. Eur J Neurol 2013 0.84
68 Prevalence of the metabolic syndrome in moderately-severely obese subjects with and without growth hormone deficiency. J Endocrinol Invest 2009 0.84
69 Cardiovascular complications of obesity in adolescents. J Endocrinol Invest 2007 0.84
70 In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. Endocrinology 1999 0.84
71 Endoscopic endonasal transsphenoidal surgery in recurrent and residual pituitary adenomas: technical note. Minim Invasive Neurosurg 2000 0.83
72 Usefulness of different biochemical markers of the insulin-like growth factor (IGF) family in diagnosing growth hormone excess and deficiency in adults. J Clin Endocrinol Metab 2001 0.83
73 Lifestyle changes in the management of adulthood and childhood obesity. Minerva Endocrinol 2014 0.83
74 Secretive and proliferative tumor profile helps to select the best imaging technique to identify postoperative persistent or relapsing medullary thyroid cancer. Endocr Relat Cancer 2008 0.83
75 Role of IGF-I on PTH effects on bone. J Endocrinol Invest 2010 0.82
76 Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro. J Clin Endocrinol Metab 2000 0.82
77 Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies. Osteoporos Int 2003 0.82
78 Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly. A prospective multi-center study. J Endocrinol Invest 2002 0.82
79 Genetic analysis of the follicle stimulating hormone receptor gene in women with polycystic ovary syndrome. J Endocrinol Invest 2006 0.81
80 Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy. J Endocrinol Invest 2009 0.81
81 Autoimmunity as a possible cause of growth hormone deficiency. J Endocrinol Invest 2008 0.81
82 Occurrence of GH deficiency in adult patients who underwent neurosurgery in the hypothalamus-pituitary area for non-functioning tumour masses. Growth Horm IGF Res 2003 0.81
83 Associated hormonal decline in aging: is there a role for GH therapy in aging men? J Endocrinol Invest 2005 0.81
84 Usefulness of [111In-DTPA0] octreotide scintigraphy in a family with von Hippel-Lindau disease. J Endocrinol Invest 2008 0.81
85 Thyroid diseases in elderly. Minerva Endocrinol 2011 0.81
86 Insulin-like growth factor (IGF)-I and IGF-binding protein-3 serum levels in relapsing-remitting and secondary progressive multiple sclerosis patients. Eur J Neurol 2011 0.81
87 Role of UGT1A1 and ADH gene polymorphisms in pegvisomant-induced liver toxicity in acromegalic patients. Eur J Endocrinol 2013 0.81
88 Hyperinsulinemic hypoglycemia associated with ectopic Cushing's syndrome due to a pancreatic endocrine tumor in a Type 2 diabetes mellitus patient: clinical implications of a rare association. J Endocrinol Invest 2010 0.81
89 Body fat in men with prolactinoma. J Endocrinol Invest 2008 0.81
90 Central diabetes insipidus and heart: effect of acute arginine vasopressin deficiency and replacement treatment with desmopressin on cardiac performance. Clin Endocrinol (Oxf) 2001 0.80
91 Pharmacotherapy or surgery as primary treatment for acromegaly? Drugs Aging 2000 0.80
92 Association of pelvic endometriosis with alopecia universalis, autoimmune thyroiditis and multiple sclerosis. J Endocrinol Invest 2006 0.80
93 The roles of parathyroid hormone in bone remodeling: prospects for novel therapeutics. J Endocrinol Invest 2011 0.80
94 The metabolic profile in active acromegaly is gender-specific. J Clin Endocrinol Metab 2012 0.80
95 Epidemiology of non-gastroenteropancreatic (neuro)endocrine tumours. Clin Endocrinol (Oxf) 2007 0.80
96 Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study. J Endocrinol Invest 2008 0.80
97 Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Neuroendocrinology 2004 0.80
98 Evaluation of circulating levels and renal clearance of natural amino acids in patients with Cushing's disease. J Endocrinol Invest 2002 0.80
99 Bone density and turnover in young adult patients with growth hormone deficiency after 2-year growth hormone replacement according with gender. J Endocrinol Invest 2008 0.80
100 Hormonal gradients between inferior petrosal sinuses in various pituitary diseases. Acta Endocrinol (Copenh) 1992 0.79
101 Growth hormone receptor variants and response to pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. J Clin Endocrinol Metab 2011 0.79
102 Somatostatin receptors in the thymus. Ann Med 1999 0.79
103 Chronic treatment with the somatostatin analog octreotide improves cardiac abnormalities in acromegaly. J Clin Endocrinol Metab 1993 0.79
104 Screening of pancreaticoduodenal endocrine tumours in patients with MEN 1: multidetector-row computed tomography vs. endoscopic ultrasound. Radiol Med 2011 0.79
105 Efficacy of combined treatment with lanreotide and cabergoline in selected therapy-resistant acromegalic patients. Pituitary 1999 0.79
106 Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. J Clin Endocrinol Metab 1997 0.79
107 Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism. Endocrine 2011 0.79
108 Effect of long-term cabergoline therapy on the immunological pattern and pituitary function of patients with idiopathic hyperprolactinaemia positive for antipituitary antibodies. Clin Endocrinol (Oxf) 2008 0.79
109 Urinary excretion of 5-hydroxy-3-indoleacetic acid in dystimic/depressed, adult obese women: what correlations to hepatic steatosis? Int J Immunopathol Pharmacol 2011 0.79
110 Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours. Clin Endocrinol (Oxf) 2014 0.79
111 Beta-endorphin concentrations both in plasma and in cerebrospinal fluid in response to acute painful stimuli. J Neurosurg Sci 1991 0.79
112 GLP-1: benefits beyond pancreas. J Endocrinol Invest 2014 0.79
113 Hormonal and seminal evaluation of Leydig cell tumour patients before and after orchiectomy. Andrologia 2000 0.78
114 Hypothalamic-pituitary-adrenal axis in neuropsychiatric disorders. Ann N Y Acad Sci 1994 0.78
115 Immunohistochemical localization and quantitative expression of somatostatin receptors in normal human spleen and thymus: Implications for the in vivo visualization during somatostatin receptor scintigraphy. J Endocrinol Invest 2011 0.78
116 [Somatostatin receptors in immune system cells]. Minerva Endocrinol 2001 0.78
117 Cardiological aspects of growth hormone and insulin-like growth factor-I. J Pediatr Endocrinol Metab 1998 0.78
118 Plasma prolactin levels in the inferior petrosal sinuses in various pituitary disorders during perihypophyseal phlebography. Neuroendocrinology 1987 0.78
119 Reevaluation of growth hormone (GH) secretion in 69 adults diagnosed as GH-deficient patients during childhood. J Clin Endocrinol Metab 1996 0.78
120 Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus. J Clin Endocrinol Metab 1999 0.78
121 Physiological and pathophysiological role of somatostatin receptors in the human thymus. Eur J Endocrinol 2000 0.78
122 Growth hormone and cardiac function. Ann Endocrinol (Paris) 2000 0.78
123 Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR). Clin Endocrinol (Oxf) 1990 0.78
124 A decrease of calcitonin serum concentrations less than 50 percent 30 minutes after thyroid surgery suggests incomplete C-cell tumor tissue removal. J Clin Endocrinol Metab 2010 0.77
125 Uncommon clinical course of multiple osteochondromatosis in a patient with a long-term history of Cushing's disease. Pituitary 2001 0.77
126 Is ovulation induction still a therapeutic problem in patients with polycystic ovary syndrome? J Endocrinol Invest 2004 0.77
127 The role for growth hormone in linking arthritis, osteoporosis, and body composition. J Endocrinol Invest 2007 0.77
128 Oral and injectable long-lasting bromocriptine preparations in hyperprolactinemia: comparison of their prolactin lowering activity, tolerability and safety. Gynecol Endocrinol 1991 0.77
129 A longitudinal study of vasopressin cell antibodies, posterior pituitary function, and magnetic resonance imaging evaluations in subclinical autoimmune central diabetes insipidus. J Clin Endocrinol Metab 1999 0.77
130 Effect of growth hormone on cardiac function. Horm Res 1997 0.77
131 Ankle brachial pressure index usefulness as predictor factor for coronary heart disease in diabetic patients. J Endocrinol Invest 2007 0.77
132 In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. Clin Endocrinol (Oxf) 2001 0.77
133 Percutaneous ethanol injection under Power Doppler ultrasound assistance in the treatment of autonomously functioning thyroid nodules. J Endocrinol Invest 1999 0.77
134 Glycometabolic control in acromegalic patients with diabetes: a study of the effects of different treatments for growth hormone excess and for hyperglycemia. J Endocrinol Invest 2011 0.77
135 Effects of a chronic treatment with octreotide in patients with functionless pituitary adenomas. Horm Res 1993 0.77
136 Impairment of bone status in patients with central diabetes insipidus. J Clin Endocrinol Metab 1998 0.77
137 Effect of a short-term treatment with recombinant growth hormone (GH) on adrenal responsiveness to corticotrophin stimulation in children affected by isolated GH deficiency. J Clin Endocrinol Metab 1992 0.77
138 Power Doppler ultrasonographic assistance in percutaneous ethanol injection of autonomously functioning thyroid nodules. J Ultrasound Med 2000 0.77
139 Corticotropin-releasing hormone test: improvement of the diagnostic accuracy of simultaneous and bilateral inferior petrosal sinus sampling in patients with Cushing syndrome. World J Surg 1995 0.77
140 Improved left ventricular function after growth hormone replacement in patients with hypopituitarism: assessment with radionuclide angiography. Eur J Nucl Med 1996 0.77
141 Impaired bone metabolism in glycogen storage disease type 1 is associated with poor metabolic control in type 1a and with granulocyte colony-stimulating factor therapy in type 1b. Horm Res Paediatr 2013 0.77
142 Cardiovascular aspects in acromegaly: effects of treatment. Metabolism 1996 0.77
143 Cryptozoospermia with normal testicular function after allogeneic stem cell transplantation: a case report. Hum Reprod 2006 0.77
144 The role of somatostatin receptors in the medical treatment of acromegaly. Dig Liver Dis 2004 0.77
145 The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. J Endocrinol Invest 2010 0.77
146 Different degrees of GH deficiency evidenced by GHRH+arginine test and IGF-I levels in adults with pituritary disease. J Endocrinol Invest 2005 0.76
147 Technetium-99m pentavalent dimercaptosuccinic acid imaging in patients with pituitary adenomas. Eur J Endocrinol 1995 0.76
148 Somatopause: dismetabolic and bone effects. J Endocrinol Invest 2005 0.76
149 Update on epidemiology, etiology, and diagnosis of adult growth hormone deficiency. J Endocrinol Invest 2008 0.76
150 Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group. J Endocrinol Invest 2011 0.76
151 FSH treatment improves sperm function in patients after varicocelectomy. J Endocrinol Invest 2000 0.76
152 Impaired cardiac performance is a distinct feature of uncomplicated acromegaly. J Clin Endocrinol Metab 1994 0.76
153 Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas. Pharmacogenomics J 2008 0.76
154 The management of the patient with acromegaly and headache: a still open clinical challenge. J Endocrinol Invest 2008 0.76
155 The manifesto A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) study group one year later: what to keep and what to amend? J Endocrinol Invest 2007 0.76
156 Epidemiology, diagnosis, and treatment of male hypogonadotropic hypogonadism. J Endocrinol Invest 2009 0.76
157 Effects of neridronate treatment in elderly women with osteoporosis. J Endocrinol Invest 2005 0.76
158 Preliminary data on effects of metformin on PED/PEA-15 cellular levels in obese women with polycystic ovary syndrome. J Endocrinol Invest 2010 0.76
159 Evaluation of function and structure of arterial wall in girls and young women with Turner syndrome. J Endocrinol Invest 2015 0.76
160 Neuroendocrine aspects of immunolymphoproliferative diseases. Ann Oncol 2001 0.76
161 Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases. J Endocrinol Invest 2001 0.75
162 Effects of two years of growth hormone (GH) replacement therapy on bone metabolism and mineral density in childhood and adulthood onset GH deficient patients. J Endocrinol Invest 1999 0.75
163 Endocrine changes (beyond diabetes) after bariatric surgery in adult life. J Endocrinol Invest 2013 0.75
164 Prolactin in inferior petrosal sinuses. Lancet 1990 0.75
165 The diagnosis of secondary adrenal insufficiency: low dose vs high dose ACTH stimulation test. J Endocrinol Invest 2003 0.75
166 The effect of chronic treatment with GH on gonadal function in men with isolated GH deficiency. Eur J Endocrinol 1999 0.75
167 Importance of spinal deformity index in risk evaluation of VCF (vertebral compression fractures) in obese subjects: prospective study. Eur Spine J 2013 0.75
168 Cortisol and the muscle-bone axis: response to comments by Molfino et al. Osteoporos Int 2015 0.75
169 MEN1 family with a novel frameshift mutation. J Endocrinol Invest 2006 0.75
170 Muscle sympathetic nerve activity in patients with acromegaly. J Clin Endocrinol Metab 2000 0.75
171 Prolactinomas apparently resistant to quinagolide respond to cabergoline therapy. J Clin Endocrinol Metab 1997 0.75
172 Role of somatostatin analogs in the management of non-functioning neuroendocrine tumors. J Endocrinol Invest 2003 0.75
173 Comparison of six months therapy with octreotide versus lanreotide in acromegalic patients: a retrospective study. Clin Endocrinol (Oxf) 1999 0.75
174 Effectiveness and long-term tolerability of the slow release oral form of bromocriptine on tumoral and non-tumoral hyperprolactinemia. J Endocrinol Invest 1992 0.75
175 Bone mineral density and circulating cytokines in patients with acromegaly. J Endocrinol Invest 1998 0.75
176 The role of somatostatin analogs in the management of hepatocellular carcinoma. J Endocrinol Invest 2003 0.75
177 Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1. Minerva Endocrinol 2013 0.75
178 Cardiac effect of thyrotoxicosis in acromegaly. J Clin Endocrinol Metab 2000 0.75
179 CV 205-502 in the treatment of tumoral and non-tumoral hyperprolactinemic states. Biomed Pharmacother 1994 0.75
180 Beyond waist circumference in an adult male population of Southern Italy: Is there any role for subscapular skinfold thickness in the relationship between insulin-like growth factor-I system and metabolic parameters? J Endocrinol Invest 2012 0.75
181 Circulating endothelial progenitor cells in acromegaly. J Endocrinol Invest 2013 0.75
182 Housing discrimination toward mentally retarded persons. Except Child 1978 0.75
183 GH release after GHRH plus arginine administration in obese and overweight women with polycystic ovary syndrome. J Endocrinol Invest 2003 0.75
184 Relationship between insulin-like growth factor-1 system and exercise tolerance in patients with intermittent claudication. Int Angiol 2009 0.75
185 The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency. J Clin Endocrinol Metab 1995 0.75
186 Fixity of vocal cords and laryngocele in acromegaly. J Endocrinol Invest 1997 0.75
187 Questions and answers: what can be said by diagnostic imaging in neuroendocrine tumors? Minerva Endocrinol 2012 0.75
188 The 17β-hydroxysteroid dehydrogenase type 3 deficiency: a case report of an 18-year patient and review of the literature. Minerva Endocrinol 2013 0.75
189 Receptor imaging in the diagnosis and treatment of pituitary tumors. J Endocrinol Invest 1999 0.75
190 Further evaluation of IGF-I responsiveness to ACTH in children affected with IGHD. Horm Res 1992 0.75
191 Cardiovascular complications in acromegaly: methods of assessment. Pituitary 2001 0.75
192 Effects of tartrate thyrotropin-releasing hormone treatment on serum thyrotropin, free triiodothyronine, free thyroxine and prolactin levels in patients with spinocerebellar degeneration. Horm Res 1992 0.75
193 Adrenocorticotropin and cortisol hyperresponsiveness to hexarelin in patients with Cushing's disease bearing a pituitary microadenoma, but not in those with macroadenoma. J Clin Endocrinol Metab 1998 0.75
194 Different sensitivity to sodium valproate in healthy, non-tumoral and tumoral hyperprolactinemic subjects. J Endocrinol Invest 1997 0.75
195 Hypothalamus-pituitary-adrenal axis in central diabetes insipidus: ACTH and cortisol responsiveness to CRH administration. J Endocrinol Invest 2002 0.75
196 A novel mutation in the N-terminal region of the CYP17A1 gene in a patient with 17 alpha-hydroxylase/17,20-lyase deficiency. J Endocrinol Invest 2009 0.75
197 Very delayed hyponatremia after surgery and radiotherapy for a pituitary macroadenoma. J Endocrinol Invest 2002 0.75
198 Usefulness of CV 205-502 in a case of allergy to ergot-derived drugs. Horm Res 1992 0.75
199 Effects of short-term treatment with orlistat on growth hormone/insulin-like growth factor-I axis in obese post-menopausal women. J Endocrinol Invest 2011 0.75
200 Height, weight, height velocity of primary school population sample in Campania region. J Endocrinol Invest 1998 0.75
201 Correlation of scintigraphic results using 123I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. J Clin Endocrinol Metab 1998 0.75
202 The role of growth hormone in glucocorticoid-induced osteoporosis. J Endocrinol Invest 2008 0.75
203 Poorly differentiated small cell neuroendocrine carcinoma localized in three different endocrine glands: response to chemotherapy and octreotide LAR. J Endocrinol Invest 2005 0.75
204 Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases. Biomarkers 2013 0.75
205 Growth rate and growth hormone response to growth hormone-releasing hormone challenge in slowly growing children during chronic administration of clonidine. J Endocrinol Invest 1995 0.75
206 Tumor necrosis factor-alpha increases after corticotropin-releasing hormone administration in Cushing's disease. In vivo and in vitro studies. Neuroendocrinology 1996 0.75
207 Rationale of pre-surgical medical treatment with somatostatin analogs in acromegaly. J Endocrinol Invest 2003 0.75
208 AME Position Statement on clinical management of acromegaly. J Endocrinol Invest 2009 0.75
209 RNA expression bcl-w, a new related protein Bcl-2 family, and caspase-3 in isolated sertoli cells from pre-pubertal rat testes. J Endocrinol Invest 2002 0.75
210 Role of dehydroepiandrosterone sulfate levels on body composition after laparoscopic adjustable gastric banding in pre-menopausal morbidly obese women. J Endocrinol Invest 2005 0.75
211 Acute and chronic effects of human recombinant GH (hrGH) on adrenal steroidogenesis in children affected with isolated GH deficiency (IGHD). J Clin Endocrinol Metab 1995 0.75
212 Future direction in acromegaly - redefining control. Growth Horm IGF Res 2003 0.75
213 Appropriate use of stimulation tests and insulin-like growth factor-I in obesity. J Endocrinol Invest 2008 0.75
214 Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly. J Endocrinol Invest 2003 0.75
215 Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine. Gynecol Endocrinol 1994 0.75
216 Allergy to ergot-derived dopamine agonists. Lancet 1992 0.75
217 Clinical management of prolactinomas: a ten-year experience. Med Oncol Tumor Pharmacother 1992 0.75
218 Effects of working posture and exposure to traffic pollutants on sperm quality. J Endocrinol Invest 2009 0.75
219 Serum thyrotropin response to combined arginine and thyrotropin-releasing hormone administration provides evidence for an altered somatostatinergic tone in acromegaly. Horm Res 1992 0.75
220 The study of spontaneous GH secretion after 36-h fasting distinguishes between GH-deficient and normal adults. Clin Endocrinol (Oxf) 1999 0.75
221 Thyroid function and morphology after a successful kidney transplantation. J Endocrinol Invest 2006 0.75
222 Bilateral and simultaneous inferior petrosal sinus sampling in the early diagnosis of an ACTH-producing pituitary microadenoma and its detection by magnetic resonance one year later. Horm Res 1992 0.75
223 Somatopause: state of the art. Minerva Endocrinol 2011 0.75
224 Growth hormone secretion after baclofen administration in different phases of the menstrual cycle in healthy women. Horm Res 2001 0.75
225 Adrenal adenoma and normal androgen levels in a young woman with polycystic ovaries: a case of idiopathic hirsutism? J Endocrinol Invest 2004 0.75
226 Age-related decrease of somatostatin receptor number in the normal human thymus. Am J Physiol Endocrinol Metab 2000 0.75
227 Technetium-99m-tetrofosmin imaging of differentiated mixed thyroid cancer. J Nucl Med 1995 0.75
228 Evaluation of GH paradoxical responses to TRH and LHRH in acromegalic patients during long-term treatment with octreotide. Horm Res 1992 0.75
229 [GH deficiency in the adult]. Minerva Endocrinol 1993 0.75
230 Technetium-99m tetrofosmin imaging in thyroid diseases: comparison with Tc-99m-pertechnetate, thallium-201 and Tc-99m-methoxyisobutylisonitrile scans. Eur J Nucl Med 1996 0.75
231 Co-existence of primary hyperparathyroidism and Parkinson's disease in three patients: an incidental finding? Parkinsonism Relat Disord 2011 0.75
232 [Cardiac effects of GH]. Minerva Endocrinol 1993 0.75
233 Comparison of anterior pituitary hormone levels in the inferior petrosal sinuses and peripheral blood in various pituitary disorders during perihypophysial phlebography. Acta Endocrinol (Copenh) 1991 0.75
234 [Growth hormone and the heart]. Cardiologia 1993 0.75
235 Evaluation of GH deficiency by GHRH+arginine test and IGF-I levels in a large population of young, middle-aged and elderly patients who had undergone neurosurgery for tumor masses in the hypothalamus-pituitary area. J Endocrinol Invest 2002 0.75
236 An evaluation of patients with hyperprolactinemia: have dynamic tests had their day? J Endocrinol Invest 2003 0.75
237 Acute administration of hexarelin stimulates GH secretion during day and night in normal men. Clin Endocrinol (Oxf) 1997 0.75
238 Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study. J Endocrinol Invest 2008 0.75
239 Langerhans cell histiocytosis, diabetes insipidus, hyperprolactinemia and empty sella: a four-fold association. Report of two cases. J Endocrinol Invest 1996 0.75
240 [Simultaneous and bilateral catheterization of inferior petrosal sinuses in the diagnosis of Cushing's syndrome: basal multiple sampling and after ACTH-releasing hormone test]. Chir Ital 2001 0.75
241 Weekly clodronate treatment prevents bone loss and vertebral fractures in women with subclinical Cushing's syndrome. J Endocrinol Invest 2009 0.75